Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

6/24/24 7:16:12 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $TRIB alert in real time by email

Get the next $TRIB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TRIB

Date	Price Target	Rating	Analyst

More analyst ratings

$TRIB
Leadership Updates

Live Leadership Updates

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief Commercial Officer. Mr. Donohue brings more than 25 years of experience in the sales and marketing of healthcare products. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We are resolute in continuing to execute on our transformation agenda, which will drive greater performance and profitability in our existing product lines, including supporting continued growth in our newest r
9/3/24 9:55:00 AM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director. Mr. Ouston brings a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies across global markets. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We remain focused on our innovative, needle-free, reusable continuous glucose monitoring (CGM) technology as a key long-term growth driver for Trinity Biotech, and we
8/20/24 5:00:00 PM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Trinity Biotech Announces Appointment of A New CFO
DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer ("CFO"). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024. Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said "We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill set, combined with
7/9/24 4:05:00 PM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

$TRIB
Press Releases

Fastest customizable press release news feed in the world

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance for its next-generation continuous glucose monitoring (CGM) system. The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than 50% improvement in Mean Absolute Difference (MAD) with Trinity Biotech's redesigned CGM s
2/6/25 7:30:00 AM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system. The pre-pivotal clinical trial, which included 30 diabetic participants—primarily individuals with Type 1 diabetes—represents a significant milestone in Trinity's mission to deliver affordable, high-performance CGM technology. Trinity Biotech's redesigned ergonomic modular device features a reusable applicator and a rechargea
1/28/25 7:20:57 AM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan
DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology. Under the terms of the agreements, a deferred consideration payment of $5 million related to the acquisition of the bios
12/24/24 8:33:54 AM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

$TRIB
Financials

Live finance-specific insights

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance for its next-generation continuous glucose monitoring (CGM) system. The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than 50% improvement in Mean Absolute Difference (MAD) with Trinity Biotech's redesigned CGM s
2/6/25 7:30:00 AM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system. The pre-pivotal clinical trial, which included 30 diabetic participants—primarily individuals with Type 1 diabetes—represents a significant milestone in Trinity's mission to deliver affordable, high-performance CGM technology. Trinity Biotech's redesigned ergonomic modular device features a reusable applicator and a rechargea
1/28/25 7:20:57 AM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan
DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology. Under the terms of the agreements, a deferred consideration payment of $5 million related to the acquisition of the bios
12/24/24 8:33:54 AM ET
$TRIB
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

Chat with this insight

Recent Analyst Ratings for
$TRIB

$TRIB
Leadership Updates

Live Leadership Updates

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

Trinity Biotech Announces Appointment of A New CFO

$TRIB
SEC Filings

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

$TRIB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

SEC Form SC 13D filed by Trinity Biotech plc

$TRIB
Press Releases

Fastest customizable press release news feed in the world

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

$TRIB
Financials

Live finance-specific insights

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

Chat with this insight

Recent Analyst Ratings for $TRIB

$TRIB Leadership Updates

Live Leadership Updates

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

Trinity Biotech Announces Appointment of A New CFO

$TRIB SEC Filings

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

$TRIB Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

SEC Form SC 13D filed by Trinity Biotech plc

$TRIB Press Releases

Fastest customizable press release news feed in the world

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

$TRIB Financials

Live finance-specific insights

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Recent Analyst Ratings for
$TRIB

$TRIB
Leadership Updates

$TRIB
SEC Filings

$TRIB
Large Ownership Changes

$TRIB
Press Releases

$TRIB
Financials